VIDEO: KSI-301 could be a 'game changer' in nAMD
Click Here to Manage Email Alerts
In this video, Diana V. Do, MD, of Byers Eye Institute at Stanford University, discussed the long-term multiple-dose KSI-301 study presented at the virtual American Academy of Ophthalmology annual meeting.
Do explained that the long-term study on antibody biopolymer conjugate KSI-301 showed excellent safety and efficacy in the phase 3 trial.
“Data showed that this individual agent was very safe, effective and could be dosed every 4 to 6 months and provide sustained anti-VEGF inhibition in wet AMD, diabetic macular edema and retinal vein occlusion. This is a very exciting biologic,” Do told Healio.
Collapse
Khanani, AM. One Year and Beyond: Long-Term Multiple-Dose Study of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate with Extended Durability, in wAMD, DME, and RVO. Presented at: AAO20 Virtual Scientific Program; Nov 13-15, 2020.
Read more about
Click Here to Manage Email Alerts